Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ia Study of Tri-specific CAR19.20.22 Chimeric Antigen Receptor (CAR) T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas

NCT07168486 is registered in ClinicalTrials.gov with University of Maryland, Baltimore as lead sponsor.

NCT NCT07168486
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07168486 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ia Study of Tri-specific CAR19.20.22 Chimeric Antigen Receptor (CAR) T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas
Lead sponsor
University of Maryland, Baltimore
Phase
Phase 1
Overall status
Enrolling by invitation
Start date
October 28, 2024
Completion date
July 1, 2028
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma, chronic lymphocytic leukemia, diffuse large b cell lymphoma (dlbcl), follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, primary mediastinal large b-cell lymphoma (pmbcl), richter transformation, small lymphocytic lymphoma, transformed follicular lymphoma (tfl)